1. Home
  2. SGRP vs NCEL Comparison

SGRP vs NCEL Comparison

Compare SGRP & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SPAR Group Inc.

SGRP

SPAR Group Inc.

HOLD

Current Price

$0.84

Market Cap

18.2M

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$4.00

Market Cap

17.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGRP
NCEL
Founded
1967
2008
Country
United States
Switzerland
Employees
N/A
4
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.2M
17.2M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
SGRP
NCEL
Price
$0.84
$4.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
49.4K
22.9K
Earning Date
03-31-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,104,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.83
52 Week High
$1.41
$5.12

Technical Indicators

Market Signals
Indicator
SGRP
NCEL
Relative Strength Index (RSI) 60.26 62.64
Support Level $0.74 $2.95
Resistance Level $0.90 $4.07
Average True Range (ATR) 0.06 0.29
MACD -0.00 0.05
Stochastic Oscillator 71.45 63.20

Price Performance

Historical Comparison
SGRP
NCEL

About SGRP SPAR Group Inc.

SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. The company provides five principal types of services: Merchandising, Marketing and Category Management, Remodel and Retail Transformation, Assembly and Installation, Fulfilment and Distribution, and Business Analytics and Insights. It operates in two segments, namely the U.S. and Canada, with the majority of the revenues deriving from the U.S. segment.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: